

References – Assessing Ovarian Reserve

1. Merriam-Webster Dictionary
2. Zegers-Hochschild, F., et al., *International Committee for Monitoring Assisted Reproductive Technology (ICMART) and the World Health Organization (WHO) revised glossary of ART terminology, 2009*. Fertil Steril, 2009. 92(5): p. 1520-4.
3. Green, D.M., et al., **Fertility** of female survivors of childhood **cancer**: a report from the childhood **cancer** survivor study. J Clin Oncol, 2009. 27(16): p. 2677-85.
4. Domingues TS, Rocha AM, Serafini PC. *Tests for ovarian reserve: reliability and utility*. Curr Opin Obstet Gynecol. 2010 Aug;22(4):271-6.
5. Chiarelli, A.M., L.D. Marrett, and G. Darlington, *Early menopause and infertility in females after treatment for childhood cancer diagnosed in 1964-1988 in Ontario, Canada*. Am J Epidemiol, 1999. 150(3): p. 245-54.
6. Sklar, C.A., et al., *Premature menopause in survivors of childhood cancer: a report from the childhood cancer survivor study*. J Natl Cancer Inst, 2006. 98(13): p. 890-6.
7. Thomas-Teinturier, C., et al., *Age at menopause and its influencing factors in a cohort of survivors of childhood cancer: earlier but rarely premature*. Hum Reprod, 2013. 28(2): p. 488-95.
8. Larsen, E.C., et al., *Diminished ovarian reserve in female childhood cancer survivors with regular menstrual cycles and basal FSH <10 IU/l*. Hum Reprod, 2003. 18(2): p. 417-22.
9. Burger, H.G., *The endocrinology of the menopause*. Maturitas, 1996. 23(2): p. 129-36.
10. Richardson, S.J., V. Senikas, and J.F. Nelson, *Follicular depletion during the menopausal transition: evidence for accelerated loss and ultimate exhaustion*. J Clin Endocrinol Metab, 1987. 65(6): p. 1231-7.
11. Burger, H.G., et al., *The endocrinology of the menopausal transition: a cross-sectional study of a population-based sample*. J Clin Endocrinol Metab, 1995. 80(12): p. 3537-45.
12. Kelsey, T.W., et al., *A validated model of serum anti-mullerian hormone from conception to menopause*. PLoS One, 2011. 6(7): p. e22024.

13. van Beek, R.D., et al., *Anti-Mullerian hormone is a sensitive serum marker for gonadal function in women treated for Hodgkin's lymphoma during childhood*. J Clin Endocrinol Metab, 2007. 92(10): p. 3869-74.
14. Lie Fong, S., et al., *Assessment of ovarian reserve in adult childhood cancer survivors using anti-Mullerian hormone*. Hum Reprod, 2009. 24(4): p. 982-90.
15. Dillon, K.E., et al., *Pretreatment antimullerian hormone levels determine rate of posttherapy ovarian reserve recovery: acute changes in ovarian reserve during and after chemotherapy*. Fertil Steril, 2013. 99(2): p. 477-83.
16. Tsepelidis, S., et al., *Stable serum levels of anti-Mullerian hormone during the menstrual cycle: a prospective study in normo-ovulatory women*. Hum Reprod, 2007. 22(7): p. 1837-40.
17. van Rooij, I.A., et al., *Serum antimullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study*. Fertil Steril, 2005. 83(4): p. 979-87.
18. Broer, S.L., et al., *Anti-mullerian hormone predicts menopause: a long-term follow-up study in normoovulatory women*. J Clin Endocrinol Metab, 2011. 96(8): p. 2532-9.
19. Hagen, C.P., et al., *Serum levels of anti-Mullerian hormone as a marker of ovarian function in 926 healthy females from birth to adulthood and in 172 Turner syndrome patients*. J Clin Endocrinol Metab, 2010. 95(11): p. 5003-10.
20. Kelsey, T.W., et al., *A validated model of serum anti-mullerian hormone from conception to menopause*. PLoS One, 2011. 6(7): p. e22024.
21. Children's Oncology Group Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent and Young Adult Cancers, version 4.0. October 2013.